Politics and Legality
Psychedelic Spotlight
2022-08-26
Breaking: DEA Backs Off, Won’t Criminalize Two New Psychedelics
The DEA backs off announces they are withdrawing a proposed rule to ban the psychedelic drugs DOI and DOC, at least for now
Share:
Related News
Live and Awake in LA
Having attended the surprisingly few SoCal events over the past few years, it was such a welcome pleasure to see familiar faces coming together in LA for 3 days of meaningful conversations centered around healing, community, access, learning, and networking at Psychedelic Awakening 2025 hosted by Psychedelic Institute of Los Angeles.
Read More
DEA Calls For Increased Production Of Some Psychedelics For Research, As Marijuana Quotas Level Out Ahead Of Scheduling Decision
The Drug Enforcement Administration (DEA) has released new quotas for the production of Schedule I and Schedule II controlled substances for research purposes—calling for an increase in the manufacturing of the psychedelics ibogaine, psilocybin and psilocyn, while continuing to maintain stable quotas for other substances such as marijuana, THC and MDMA. As DEA prepares to […]
Read More
Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming “No” Vote
Following last week’s negative headlines, we review how Lykos Therapeutics unsuccessfully sought to reassure the committee, how its apparent policy of minimal engagement might have backfired…
Read More
Top VA Official Says Psychedelics Have “Surpassed” Marijuana In Bipartisan Acceptance In Congress
A top official with the U.S. Department of Veterans Affairs (VA) says there’s an “unstoppable narrative” in support of advancing psychedelic medicine, with a combination of compelling personal stories of recovery and robust clinical data from studies he’s hoping to expand upon. He also said bipartisan acceptance of psychedelics has “surpassed” that of marijuana in […]
Read More